Fortis Healthcare Limited

rs,

tement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian

29%

while promoter group company. EHIRCL also could not directly takeover the loan, as EHIRCL (holding 29%) could not have taken over the burden of the entire debt of Healthstaff. Therefore, this transacti

71 %

althstaff. Therefore, this transaction was in a way to help the erstwhile promoter group companies( 71 % shareholders) to avoid making payment for its share, and place EHIRCL in a situation where it woul

51 %

018, the Company through its subsidiary (i.e. Fortis Hospitals Limited ("FHsL")), purchased further 51 % equity interest in Fortis Emergency Services Limited (FESL) at an aggregate consideration of Rupees

49%

erstwhile promoter group company. FHsL also could not directly takeover the loan, as FHsL (holding 49%) could not have taken over the burden of the entire debt of FESL. Therefore, this transaction was i

51%

ebt of FESL. Therefore, this transaction was in a way to help the erstwhile promoter group company (51% shareholders) to avoid making payment for its share, and place FHsL in a situation where it would f

50%

until business became normal with the consent of both the Company and its subsidiaries. Accordingly 50% waiver of fixed service fee for the third quarter (Oct-Dec 2020) was approved by the subsidiaries k

Rs 350 crore

tics Private Limited' (DDRC SRL) by SRL Limited, a material subsidiary, for a cash consideration of Rs 350 crores. During the previous quarter, the said transaction was consummated on April 5, 2021. The acquisiti

100%

e same line of business as that of entity being acquired. Post this acquisition DDRC SRL has become 100% subsidiary of SRL Group. 16. Previous period figures have been regrouped/ reclassified wherever ne

Rs. 25,344

required in the Statement. iii. As explained in Note I 2 of the Statement •. a Civil Suit claiming Rs. 25,344 lacs was filed by a third party against various entities including the Company and certain entities

rs. 7

ined on disposal of the said petition. Our conclusion is not modified in respecl of the above matters. 7. The Swtement includes the interim financial information of sixiccn subsidiaries which have not bee

Rs. 45,351

nformation (before intercompany elimination and consolidation adjustments) reflects total assets of Rs. 45,351 lacs as at 30 September 2021 and total revenue of Rs. 957 lacs and Rs. 1.598 lacs. total nel loss af

“In line with guidance on accounting for such concessions that are a direct consequence of the COVID-19 pandemic, the Company has recognised an exceptional gain of Rupees 6,340 lacs for the year ended March 31, 2021.”

“Going forward, the actual impact of the Covid-19 pandemic may still be different from that what has been estimated.”

“1he management is confident 1ha11-111 PL will be able to successfully defend the termination order.”

“due to uncertainties involved, the ultimate outcome will be ascertained on disposal of the said petition.”

“In the aforesaid context, proper and sufficient care has also been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities on a going forward basis.”

“Based on the external legal counsel advice, the Company believes that EHIRCL will be able to suitably defend the termination of lease deeds and allotment letters and accordingly considers that no adjustments are required to the unaudited Consolidated Financial Results.”

“However, the significant amount of dividend in the year ended March 31, 2020 was largely on account of a one-off transaction which led to dividend payment and the Company does not expect dividend of such a significant amount to be recurring in future.”

“The Board has also noted and confirmed that such dividend does not represent Income from ordinary activities of the Company and that the Company does not intend lo carry on the business as an NBFC.”

“Going forward, the actual impact of the Covid-19 pandemic may still be different from that what has been estimated.”

“By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.”

Fax

2

Joint ventures

1

Associates

1

For further details please contact

1

Cash

1

Fax

+91124 719 1000 +91124 235 8613 To Board of Directors of Fortis Healthcare Limited I. We have reviewed the accompanying Statement of unaudited standalone financial results of Fortis Healthcare Limited ("the Company") for the quarter ended 30 September 2021 and year to date results for the period from I April 2021 to 30 September 2021 ("the Statement"). 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE

Fax

+91124119 1000 •91 124 235 8613 To Board of Directors of Fortis llcalthcarc Limited I. We have reviewed the accompanying Statement of unaudited consolidated li11ancial results of Fortis Healthcare Limited ("'the Parent" or ··the Company") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group''). and its share of the net profit after tax and total comprehensive income of its associmes and joint vcmures lbr the quarter ended 30 September 2021 and year to date results for the period from I April 2021 to 30 September 2021 (''the Stateme111"), being submitted by the Pare111 pursua111 to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015. as amended ('Listing Regulations'). 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors. has been prepared in accordance with the recognition and measurement principles laid down i11 Indian A

Associates

(i) (ii) (iii) (iv) Fortis Cauvery Fortis C- Doc I lealthcare Limited RL Diagnostics (Nepal) Pri, ate Limited DDRC 'RI. Diagnostics Private Limited (lilt •I April 2021) Sunrise Medicari.: Private Limited (till 17 August 202 I) Lanka I lospitals Corporate Pie Tl IR Infrastructure Pte Ltd Rf IT I feullh Trust 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our nttention that causes us lo believe that the accompanying Statement. prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounling Standard nnd other accounting principles generally accepted in India. has not disclosed the information required to be disclosed in terms or Regulation 33 or the Lisling Regulations. including the manner in which it is to be disclosed. or that it contains any material misslatemcnt. BS R & Co. LLP 6. We draw attention 10 1he following Notes in the S1atemen1: i. Note 7 and 8 of the Statement

For further details please contact

Anurag Kalra / Gaurav Chugh Investor Relations +91-9810109253 / 9958588900 Fortis Healthcare Limited Ajey Maharaj Corporate Communication +91-9871798573 Fortis Healthcare Limited 4/4 November 12, 2021 DISCLAIMER This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities of the c

Cash

Domestic, 42.3% Cash : Domestic, 40.0% Pvt Corps, 1.2% Govt & PSUs, 9.0% International , 1.3% CGHS, 3.1% ECHS, 5.5% Pvt Corps, 0.8% Govt & PSUs, 9.6% International , 3.6% CGHS, 3.1% ECHS, 4.6% Decline in Cash business being primarily compensated by TPAs, Medical Tourism and Govt business HOSPITAL BUSINESS PERFORMANCE Facilities across the network witnessed a healthy growth in revenues 137 83 118 92 98 63 92 70 91 89 56 56 84 54 Q2FY21 Q2FY22 59 40 50 37 47 31 FMRI Mohali BG Road Mulund FEHI Shalimar Bagh Noida Anandpur Faridabad Jaipur 137 131 118 108 98 81 89 92 91 76 89 82 84 71 Q1FY22 Q2FY22 64 59 45 50 43 47 FMRI Mohali BG Road Mulund FEHI Shalimar Bagh Noida Anandpur Faridabad Jaipur All figures in INR Crs. HOSPITAL MARGIN MATRIX 2 2 Y F 2 Q 1 2 Y F 4 Q EBITDA No of Facilities Revenue Contribution Operational beds ARPOB (INR Cr) Occupancy >25% 20% - 25% 15% - 20% 10% - 15% <10% 6 5 3 4 5 39% 14% 17% 22% 8% 1,288 722 490 805 553 2.13 1.21 2.40 1.98 1.39 66% 73% 67% 64% 47% EBITDA N